--- title: "CSPC Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now" type: "News" locale: "en" url: "https://longbridge.com/en/news/288127646.md" description: "CSPC Pharmaceutical Group missed Q1 earnings estimates by 33%, causing a 2.5% share drop. However, analysts have upgraded 2026 forecasts, projecting revenue growth of 24% to CN¥31.5b and EPS surge of 154% to CN¥0.72. Despite these positive sentiment shifts and expectations of faster growth than the industry, the consensus price target remains unchanged at HK$11.46, reflecting divergent analyst views." datetime: "2026-05-30T01:24:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288127646.md) - [en](https://longbridge.com/en/news/288127646.md) - [zh-HK](https://longbridge.com/zh-HK/news/288127646.md) --- # CSPC Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now Shareholders might have noticed that **CSPC Pharmaceutical Group Limited** (HKG:1093) filed its quarterly result this time last week. The early response was not positive, with shares down 2.5% to HK$7.50 in the past week. It looks like a pretty bad result, all things considered. Although revenues of CN¥6.6b were in line with analyst predictions, statutory earnings fell badly short, missing estimates by 33% to hit CN¥0.077 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. SEHK:1093 Earnings and Revenue Growth May 30th 2026 Taking into account the latest results, the most recent consensus for CSPC Pharmaceutical Group from 20 analysts is for revenues of CN¥31.5b in 2026. If met, it would imply a major 24% increase on its revenue over the past 12 months. Per-share earnings are expected to shoot up 154% to CN¥0.72. In the lead-up to this report, the analysts had been modelling revenues of CN¥30.0b and earnings per share (EPS) of CN¥0.58 in 2026. There's been a pretty noticeable increase in sentiment, with the analysts upgrading revenues and making a considerable lift to earnings per share in particular. View our latest analysis for CSPC Pharmaceutical Group Despite these upgrades,the analysts have not made any major changes to their price target of HK$11.46, suggesting that the higher estimates are not likely to have a long term impact on what the stock is worth. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on CSPC Pharmaceutical Group, with the most bullish analyst valuing it at HK$19.36 and the most bearish at HK$6.00 per share. As you can see the range of estimates is wide, with the lowest valuation coming in at less than half the most bullish estimate, suggesting there are some strongly diverging views on how analysts think this business will perform. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business. Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. One thing stands out from these estimates, which is that CSPC Pharmaceutical Group is forecast to grow faster in the future than it has in the past, with revenues expected to display 33% annualised growth until the end of 2026. If achieved, this would be a much better result than the 0.5% annual decline over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 11% annually. Not only are CSPC Pharmaceutical Group's revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry. ## The Bottom Line The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around CSPC Pharmaceutical Group's earnings potential next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. The consensus price target held steady at HK$11.46, with the latest estimates not enough to have an impact on their price targets. Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple CSPC Pharmaceutical Group analysts - going out to 2028, and you can see them free on our platform here. Even so, be aware that CSPC Pharmaceutical Group is showing **1 warning sign in our investment analysis** , you should know about... ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [01093.HK](https://longbridge.com/en/quote/01093.HK.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [520500.CN](https://longbridge.com/en/quote/520500.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [562050.CN](https://longbridge.com/en/quote/562050.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) ## Related News & Research - [CICC Sticks to Their Buy Rating for CSPC Pharmaceutical Group (CHJTF)](https://longbridge.com/en/news/288013817.md) - [Kelun-Biotech's Sac-TMT + Pembrolizumab Improves Survival In Late-Stage China Trial](https://longbridge.com/en/news/287276752.md) - [3D Medicines’ Envafolimab Trial in Biliary Tract Cancer to Headline 2026 ASCO Meeting](https://longbridge.com/en/news/287699826.md) - [Nanjing Leads Biolabs Showcases Promising Opamtistomig Data Ahead of 2026 Lung Cancer Summit](https://longbridge.com/en/news/287858670.md) - [China pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says](https://longbridge.com/en/news/287629559.md)